Karyopharm Financial Statements From 2010 to 2025

KPTI Stock  USD 6.14  0.61  9.04%   
Karyopharm Therapeutics financial statements provide useful quarterly and yearly information to potential Karyopharm Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Karyopharm Therapeutics financial statements helps investors assess Karyopharm Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Karyopharm Therapeutics' valuation are summarized below:
Gross Profit
139.2 M
Profit Margin
(0.53)
Market Capitalization
56.8 M
Enterprise Value Revenue
0.9826
Revenue
145.2 M
We have found one hundred twenty available fundamental ratios for Karyopharm Therapeutics, which can be analyzed and compared to other ratios and to its peers in the industry. Traders should compare all of Karyopharm Therapeutics last-minute fundamentals against the fundamentals between 2010 and 2025 to make sure the company is sustainable this year. The current Market Cap is estimated to decrease to about 5.6 B. Enterprise Value is estimated to decrease to about 5.6 B

Karyopharm Therapeutics Total Revenue

152.5 Million

Check Karyopharm Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Karyopharm Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 323 K, Interest Expense of 39.3 M or Selling General Administrative of 71.8 M, as well as many indicators such as Price To Sales Ratio of 8.08, Dividend Yield of 0.0 or Days Sales Outstanding of 54.26. Karyopharm financial statements analysis is a perfect complement when working with Karyopharm Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Karyopharm Therapeutics Correlation against competitors.
For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.

Karyopharm Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets234.2 M164.4 M201.4 M
Slightly volatile
Total Current Liabilities96.9 M92.3 M37.1 M
Slightly volatile
Property Plant And Equipment Net3.3 M6.3 M2.8 M
Slightly volatile
Current Deferred Revenue15.7 M28.8 M16.5 M
Slightly volatile
Accounts Payable3.7 M5.1 M3.2 M
Slightly volatile
Cash99.3 M62.5 M85.6 M
Slightly volatile
Non Current Assets Total7.5 M7.9 M17.8 M
Pretty Stable
Other Assets1.091.155.3 M
Pretty Stable
Cash And Short Term Investments195.8 M108.7 M168.4 M
Slightly volatile
Common Stock Shares Outstanding133.1 M126.8 M55.2 M
Slightly volatile
Liabilities And Stockholders Equity234.2 M164.4 M201.4 M
Slightly volatile
Non Current Liabilities Total156.8 M258.2 M135.6 M
Slightly volatile
Other Current Assets6.7 M12.3 M5.8 M
Slightly volatile
Other Stockholder Equity803.7 M1.4 B689.5 M
Slightly volatile
Total Liabilities181.1 M350.4 M156.6 M
Slightly volatile
Property Plant And Equipment Gross13.6 M13 M5.2 M
Slightly volatile
Total Current Assets212.5 M156.5 M182.7 M
Slightly volatile
Short Term Debt832.2 K876 K8.9 M
Pretty Stable
Property Plant Equipment2.2 M1.3 M1.8 M
Pretty Stable
Common Stock Total Equity14.5 K13.8 K6.8 K
Slightly volatile
Capital Surpluse824.8 M1.5 B739.4 M
Slightly volatile
Common Stock7.7 K13 K6.3 K
Slightly volatile
Other Liabilities260.4 M248 M87.2 M
Slightly volatile
Net Invested Capital1.3 M1.4 M126.7 M
Slightly volatile
Net Working Capital61 M64.2 M144 M
Slightly volatile
Short and Long Term Debt Total155 M99.9 M139.1 M
Pretty Stable
Long Term Debt Total121.2 M135.6 M110.1 M
Slightly volatile
Capital Stock10.2 K13 K7.7 K
Slightly volatile
Net Receivables27.1 M30.8 M15.4 M
Slightly volatile
Capital Lease Obligations8.2 M7.2 M12.7 M
Slightly volatile
Non Current Liabilities Other2.3 M2.4 M69.5 M
Slightly volatile
Short and Long Term Debt19.5 M22 M24 M
Slightly volatile

Karyopharm Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization323 K340 K985.1 K
Pretty Stable
Selling General Administrative71.8 M115.4 M61.7 M
Slightly volatile
Total Revenue152.5 M145.2 M62.1 M
Slightly volatile
Gross Profit146.2 M139.2 M60.2 M
Slightly volatile
Other Operating Expenses186 M264.7 M160.3 M
Slightly volatile
Research Development112.3 M143.2 M96.9 M
Slightly volatile
Cost Of Revenue5.7 MM39.4 M
Pretty Stable
Total Operating Expenses184.1 M258.7 M158.6 M
Slightly volatile
Non Operating Income Net Other2.1 M2.6 M1.6 M
Slightly volatile
Interest IncomeM7.4 M2.8 M
Slightly volatile
Tax Provision54.1 K57 K151.6 K
Pretty Stable
Reconciled Depreciation571 K340 K704.5 K
Slightly volatile

Karyopharm Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation18.9 M18.4 M16.2 M
Slightly volatile
Begin Period Cash Flow95.9 M53.2 M82.5 M
Slightly volatile
Total Cash From Financing Activities39.6 M41.6 M94.6 M
Pretty Stable
End Period Cash Flow100.5 M62.8 M86.7 M
Slightly volatile
Sale Purchase Of Stock104.9 M99.9 M56.9 M
Pretty Stable
Change To Netincome22.7 M40.4 M19.8 M
Slightly volatile
Net Borrowings133.5 M150.2 M163.8 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio8.088.50819.6 K
Slightly volatile
Days Sales Outstanding54.2677.319168.2975
Very volatile
Stock Based Compensation To Revenue0.120.126918.8049
Pretty Stable
EV To Sales8.338.76599.5 K
Slightly volatile
Inventory Turnover2.381.26764.8702
Slightly volatile
Days Of Inventory On Hand221288147
Slightly volatile
Payables Turnover1.121.176211.0187
Slightly volatile
Sales General And Administrative To Revenue0.760.794823.6399
Slightly volatile
Research And Ddevelopement To Revenue0.940.986294.276
Slightly volatile
Capex To Revenue0.00110.00111.4959
Slightly volatile
Cash Per Share0.850.89215.0214
Slightly volatile
Days Payables Outstanding326310137
Slightly volatile
Income Quality1.751.66820.9276
Slightly volatile
Current Ratio1.611.696168.9977
Pretty Stable
Receivables Turnover6.684.72075.6177
Pretty Stable
Capex Per Share0.00130.00130.0669
Slightly volatile
Revenue Per Share1.251.19180.738
Slightly volatile
Interest Debt Per Share1.381.1271.2955
Slightly volatile
Debt To Assets0.390.60770.3893
Slightly volatile
Operating Cycle275365215
Slightly volatile
Days Of Payables Outstanding326310137
Slightly volatile
Ebt Per Ebit0.820.63931.0084
Very volatile
Quick Ratio1.561.644868.4243
Pretty Stable
Net Income Per E B T0.81.00070.9887
Slightly volatile
Cash Ratio0.640.677123.8616
Very volatile
Days Of Inventory Outstanding221288147
Slightly volatile
Days Of Sales Outstanding54.2677.319168.2975
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.121.151.032
Slightly volatile
Fixed Asset Turnover15.8323.112218.3337
Slightly volatile
Debt Ratio0.390.60770.3893
Slightly volatile
Price Sales Ratio8.088.50819.6 K
Slightly volatile
Asset Turnover0.930.88330.2912
Slightly volatile

Karyopharm Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap5.6 B7.2 B6.6 B
Slightly volatile
Enterprise Value5.6 B7.2 B6.5 B
Slightly volatile

Karyopharm Fundamental Market Drivers

Cash And Short Term Investments108.7 M

Karyopharm Upcoming Events

21st of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
21st of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Karyopharm Therapeutics Financial Statements

Investors use fundamental indicators, such as Karyopharm Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Karyopharm Therapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Current Deferred Revenue28.8 M15.7 M
Total Revenue145.2 M152.5 M
Cost Of RevenueM5.7 M
Stock Based Compensation To Revenue 0.13  0.12 
Sales General And Administrative To Revenue 0.79  0.76 
Research And Ddevelopement To Revenue 0.99  0.94 
Revenue Per Share 1.19  1.25 
Ebit Per Revenue(0.82)(0.86)

Currently Active Assets on Macroaxis

When determining whether Karyopharm Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Karyopharm Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Karyopharm Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Karyopharm Therapeutics Stock:
Check out the analysis of Karyopharm Therapeutics Correlation against competitors.
For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.
You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Karyopharm Therapeutics. If investors know Karyopharm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Karyopharm Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(13.95)
Revenue Per Share
17.877
Quarterly Revenue Growth
(0.1)
Return On Assets
(0.37)
Return On Equity
(8.91)
The market value of Karyopharm Therapeutics is measured differently than its book value, which is the value of Karyopharm that is recorded on the company's balance sheet. Investors also form their own opinion of Karyopharm Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Karyopharm Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Karyopharm Therapeutics' market value can be influenced by many factors that don't directly affect Karyopharm Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Karyopharm Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Karyopharm Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Karyopharm Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.